drugset / Trial / NCT01072448

12-week Efficacy of Indacaterol

NCT01072448 ↗

Phase 3 Completed 323 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.

Timeline

Start
2010-01
Primary completion
2010-07
Completion
2010-07

Outcome

Met primary endpoint

paper At week 12, indacaterol demonstrated clinically relevant bronchodilator efficacy, increasing trough FEV(1) by ≥120 mL versus placebo (P < 0.001) PMID 22177371 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 75 ug Inhaled